COMMUNIQUÉS West-GlobeNewswire

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, [...]
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
21/05/2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting
21/05/2026
Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with the known profiles of the respective drugs. Encouraging preliminary signals [...]
NervGen Announces Proposed Public Offering of Securities
21/05/2026
The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or [...]
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York City (New York, Etats-Unis), le 21 mai 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease
21/05/2026
European designation follows U.S. FDA Orphan Drug Designation previously granted for the same indication Landmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki [...]
ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki
21/05/2026
La désignation de la Commission Européenne fait suite à la désignation médicament orphelin de la FDA américaine, précédemment accordée pour la même indication L’essai clinique KIDCARE a démontré la supériorité de l’ [...]
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany , May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company [...]
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026
Exclusive manufacturing partnership integrates point-of-origin batch testing in Malaysia with strict domestic HPLC and LC-MS verification to ensure uncompromising purity for laboratory reagents. BulkGLP Logo DALLAS, May [...]
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026
Sanofi Honored with Corporate Leadership Award; Wanda and Robert Zimmer Serve as Honorary Chairs; Sherry Graves Hope Fund for Patient Financial Support Established MINNEAPOLIS, May 21, 2026 (GLOBE NEWSWIRE) -- NMDP℠ [...]
The Joint Corp. Announces Milind Pant Elected as Director
21/05/2026
- Global Executive with Extensive Digital and International Franchise-Led Growth Experience - SCOTTSDALE, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of [...]
IQity and Sightpath Medical Partner to Deliver Advanced Ophthalmic Technology to Surgeons Nationwide
21/05/2026
RENO, Nev., May 21, 2026 (GLOBE NEWSWIRE) -- IQity, the developer of a revolutionary integrated diagnostic and surgical platform for modern ophthalmology, today announced a strategic partnership with Sightpath Medical, [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
Paul Cobbo to head leading Brisbane NDIS provider Orange Plan Management
21/05/2026
Brisbane, QUEENSLAND, May 21, 2026 (GLOBE NEWSWIRE) -- Paul Cobbo has been appointed General Manager of nationally recognised NDIS plan manager Orange Plan Management. He brings a decade of experience with him gained [...]
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
21/05/2026
The olanzapine long-acting injectable ( TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation 1 administered every four weeks. If approved, TEV-‘749 could help fill a significant [...]
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026
Trésorerie et équivalents de trésorerie s’élevant à 136,1 millions d’euros au 31 mars 2026 Chiffre d’affaires de 9,6 millions d’euros pour les trois premiers mois de 2026, provenant des redevances issues des ventes d’ [...]
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]

Pages